Lamivudine 134678-17-4 CAS NO.134678-17-4

Min.Order Quantity:: 1 Kilogram

Purity:: 99% min

Port:: Any port of China

Payment Terms:: L/C,T/T,MoneyGram

Add to Inquiry Cart

Product Details

Keywords

134678-17-4
Lamivudine
C8H11N3O3S

Quick Details

ProName: Lamivudine 134678-17-4
CasNo: 134678-17-4
Molecular Formula: C8H11N3O3S
Appearance: white powder
Application: Lamivudine 134678-17-4
DeliveryTime: with 10 days after order confirmed
PackAge: 25kg plastic drum
Port: Any port of China
ProductionCapacity: 1 Metric Ton/Day
Purity: 99% min
Storage: room temperature
Transportation: by air
LimitNum: 1 Kilogram
Grade: Industrial Grade,Food Grade,Pharma Gra...

Superiority

our company was built in 2009 with an iso certificate.in the past 5 years, we have grown up as a famous fine chemicals supplier in china and we had established stable business relationships with samsung,lg,merck,thermo fisher scientific and so on.our main business covers the fields below:

1.noble metal catalysts (pt.pd...)

2.organic phosphine ligands (tert-butyl-phosphine.cyclohexyl-phosphine...)

3.oled intermediates (fluorene,carbazole,boric acid...)

4.customs synthesis

our advantage:

1. higest quality and good package

2.fast delivery

3.better payment term

4.fast response to customer within 6 hours

5.good business credit in europe ,us ,japan ,korea

anyway ,if you need any chemicals from china ,henan tianfu can help you

Details

lamivudine basic information

new antiviral drug indications methods of production what kind of patients suitable for use lamivudine entecavir pharmacokinetics drug withdrawal adverse reactions and side effects disabling condition chemical property application

product name:	lamivudine
synonyms:	(-)-bch-189;(-)-beta-l-2',3'-dideoxy-3'-thiacytidine;(-)-b-l-2',3'-dideoxy-3'-thiacytidine;(2r-cis)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone;2'-deoxy-3'-thiacytidine;4-amino-1-((2r,5s)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1h-pyrimidin-2-one;3tc;3'-thia-2',3'-dideoxycytidine
cas:	134678-17-4
mf:	c8h11n3o3s
mw:	229.26
einecs:
product categories:	active pharmaceutical ingredients;antivirals for research and experimental use;biochemistry;chemical reagents for pharmacology research;nucleosides and their analogs;nucleosides, nucleotides & related reagents;anti-virals;intermediates & fine chemicals;pharmaceuticals;api's;hiv/aids/related products;sulfur & selenium compounds;api;dendrid
mol file:	134678-17-4.mol

lamivudine chemical properties

mp	177 °c
refractive index	-142 ° (c=1, meoh)
storage temp.	freezer
merck	5352
cas database reference	134678-17-4(cas database reference)

safety information

risk statements	63
rtecs	uw7361333
hazardous substances data	134678-17-4(hazardous substances data)

msds information

provider	language
(2r-cis)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone	english

lamivudine usage and synthesis

new antiviral drug	lamivudine is a new antiviral drug, belonging to nucleoside reverse transcriptase inhibitors, having a strong inhibitory effect in vitro and animal experimental infection of hepatitis b virus (hbv), can inhibit the synthesis of hiv virus; the drug produced by the glaxosmithkline co. in the early 90s, they are used for the treatment of aids drugs in europe and north american countries. in the middle of the 1990 medical experts found that they have inhibition to hepatitis b virus dna, in 1998 the united states food and drug administration (fda) approved the first drug for treatment of hepatitis b treatment. in china, the state food and drug administration approved the drug import mainly used as medicine in the treatment of hepatitis b, chinese product name as "he puding". in 1999, officially began on the mainland. chinese sold after 10 years of clinical verification, lamivudine is the only proven to delay hepatitis cirrhosis progress, fewer side effects, less cost of medication, currently has 2 million of the country's hepatitis b patients are using. lamivudine can be metabolized to lamivudine three phosphate in hbv infection cells and normal cells, it is the active form of lamivudine, both inhibitors of hbv polymerase, and is polymerase substrate. lamivudine three phosphate incorporation into viral dna chain, can block the synthesis of viral dna, and does not interfere with normal cell deoxynucleoside metabolism, having weak inhibition to mammalian dna polymerase alpha and beta, almost no effect on mammalian cell dna content, and without obvious toxicity to the structure of mitochondria, content and function of dna. for serum hbv-dna detection results of most hepatitis b patients showed that lamivudine can rapidly inhibit the replication of hbv, its inhibitory effect lasted for the entire treatment process. at the same time the serum transaminase decreased to normal, long-term use can significantly improve the liver necrosis and inflammatory changes in relieve or prevent liver fibrosis.
indications	hepatitis b, hepatitis b virus replication of chronic hepatitis b.
methods of production	select 6-o-sulfo acylation reaction to the compounds (i), then acetylated to obtaine compound (ii), the yield was 96.7%. the compound (ii) uses acetic acid as solvent, and 3 mol hydrogen bromide / l acid (45%, w/v) reaction, bromination to get compound (iii), the yield was 99%. bromide (iii) and 3.3 moi ethyl potassium xanthate, refluxing in acetone, thio and cyclization; then in methanol with ammonia hydrolysis to obtain the compound (iv), the second step yield is 72%. compounds (iv) is purified by column chromatography, is crystalline solid. compound (iv) uses 1.4 mol sodium periodate treatment to make 2,3- cis glycol open; followed by sodium borohydride reduction to aldehydes and shrinkage the keto form to protect the glycol, and obtain compound (v), the yield is 60%. the compound (v) silane to protect the rest of the primary alcohol, and then take off ketal to obtain compound (vi) and yield is 63%.use lead tetraacetate to oxidize glycol of compounds (vi), and then to use dichromic acid pyridine salt to further oxidation, and obtain compound (vii), the oxidation method does not affect the sulfur. compounds (vii) is oxidized by using lead acetate to obtain compounds (viii), the yield is 66%[ according to compounds (vi)]. compounds (viii) and (ix) are in the dichloroethane,and tmsotf as a lewis acid catalyst, condensated to compound (x), the yield is 64%. and the amount of isomers of compounds (x) is half of the compounds (x) and their available silica gel chromatography to isolate. compounds (x) in ammonia - methanol and acetyl, the yield is 73% ; with tetrabutylammonium fluoride solution to remove the silylation to obtain lamivudine and yield of 75%.
what kind of patients suitable for use lamivudine	not all patients with hepatitis b are suitable for the use of lamivudine. lamivudine should be applied in the following cases according to the action characteristics of lamivudine and clinical summary of the experience in the application of lamivudine: (1) hbvdna quantitative detection of moderate positive; hbeag positive; alt increased 2 ~ 10 times. (2) hbeag negative, but hbvdna was moderately positive (do not take the qualitative pcr results as the standard, to do quantitative measurement), alt increased 2 ~ 10 times. the majority of this situation may be the virus gene mutations in the c region. not suitable for the use of lamivudine is the main: (1) hbvdna negative or quantitative determination of <105copies/ml; (2)with normal alt (mainly refers to the virus asymptomatic hbv carriers (asc); for the past elevated alt, but now alt and ast normal patients, can be temporary not treatment, elevated alt and treated. the patient was not suitable for use, not because lamivudine is harmful to the people, but because of the low effective rate of these patients, does not meet the pharmaceutical economics principle. lamivudine, like any other drugs, can be used properly to benefit most patients, and inappropriate use will not produce the desired effect, and inappropriate withdrawal may even lead to exacerbations. the above information is chemicalbook hanya edited.
entecavir	en entecavir is a new generation of guanine nucleoside analogues oral medicine for treatment of hepatitis b virus infection in, mainly for the treatment of adult patients with viral replication activity and serum transaminase continued to increase, or liver tissue for pathological activity of chronic hepatitis b, is currently down virus the fastest and the most powerful, the mutation rate lowest nucleoside analogues. data show that different in patients with chronic hepatitis b, including nucleoside naive and nucleoside treated and liver cirrhosis patients, using well entecavir tablets in the treatment can control the disease rapidly and easily reach the treatment of reality end, namely the hepatitis b virus unmeasured; through adherence to treatment, a considerable portion of patients can be arrived at the end of treatment satisfaction, namely e antigen serology conversion, some patients can even reach the ideal for the treatment of end, namely surface antigen negative.
pharmacokinetics	after oral administration of lamivudine, it is well absorbed. and about 0.1 g of adult oral about 1hr reached peak plasma concentration cmax 1.1-1.5 u g / ml, bioavailability is 80-85%. and at the same time of food taking, the tmax delayed 0.25-2.5 hr and lower 10-40% of cmax, but the bioavailability is unchanged. intravenous administration research results table ming lamivudine average distribution capacity is 1.3 l/kg, system average clearance rate of 0.3 l / h / kg, seventy percent by organic cation transport system and renal clearance and elimination half-life is 5-7hr. within the therapeutic dose range and lamivudine pharmacokinetics showed a linear relationship, the plasma protein binding rate is low. in vitro studies have shown that with serum albumin binding rate is <16-36%. it can pass through the blood brain barrier into the cerebrospinal fluid. mainly the prototype drug excretion by the kidneys, renal excretion accounted for about total removal of 70% or so, only 5-10% is metabolized into anti sulfur oxide derivatives. for patients with renal insufficiency can affect lamivudine excretion, and for creatinine clearance rate <30ml/ points in patients, does not recommend the use of this product. liver damage does not affect the metabolism of drugs, due to increased age and decreased renal excretory function in elderly patients, lamivudine metabolism without significant changes, only in creatinine clear except rate <30ml/ time-sharing, there is influence.
drug withdrawal	lamivudine is not hepatitis b curative drugs, can only make it better, and easy to rebound after discontinuation of lamivudine treatment. so how long is more appropriate, should according to the therapeutic effect and it differs from man to man. the most accepted standard of withdrawal is: before treatment, hbvdna positive, hbeag positive, alt increased more than 1 times; treatment after hbvdna seroconversion, hbeag seroconversion ("big sanyang" to "small sanyang"), alt normalization, maintain the effect of the above 6 months can be stopped. of course in this standard withdrawal is not only without recurrence, the recurrence rate is low. it is reported that this group of patients discontinued 21 months still maintain curative effect. the recurrence rate of 81%. asians is slightly higher, but in a year when the recurrence rate is lower than that of 40%. for example not up to this effect and withdrawal, while the majority of cases in a short period of time to recurrence, even some patients because of inappropriate drug withdrawal and lead to illness. so stoping the drug is a great event, i hope the patients in the decision to stop the medicine to go to the hospital to consult an experienced specialist, and not to stop the medicine.
adverse reactions and side effects	lamivudine is a kind of nucleoside drugs, by inhibiting or blocking synthesis of the hepatitis b virus dna to restrain replication of hepatitis b virus, thus gradually clear hepatitis b virus, often are used by doctors to treat acute and chronic hepatitis b. common side effects are easy to produce drug resistance, side effects, withdrawal difficult, fever, upper respiratory tract infection symptoms, headache, abdominal pain, physical discomfort, diarrhea and other symptoms, but the symptoms are generally mild and in a short time the ego recede. at the same time the state food and drug administration released thirtieth phase drug adverse reaction information bulletin also alert our medical workers and drug producers wary of lamivudine and telbivudine may cause the risk of rhabdomyolysis, myalgia, weakness, elevated creatine kinase, blood creatinine rise higher. long-term use is easily virus mutates, more performance is after discontinuation of hepatitis b virus dna positive rotation or is in a cycle of treatment occurs when the hepatitis b virus positive turn, this is the hallmark of virus mutates, indicating that more serious illness, more difficult to treat. recent studies also suggest, the side effects of lamivudine is also reflected on the damage to the kidney, the majority of patients will have different degrees of renal toxicity, serious and even renal failure.
disabling condition	1.chronic asymptomatic hepatitis b virus carriers were normal and no symptoms, whatever virus replication index or not (both "big sanyang" and "small sanyang"), are not taking lamivudine. but it is understood that at present this part of patients taking this medicine is a common phenomenon, which wasted drugs and money. at present the treatment of hepatitis b virus is not resolved, medical scientists is also exploring, the existing methods are not mature. the important reason of lamivudine in treatment of hepatitis b virus are invalid, someone after taking hbvdna may drop to 103 copies / ml, once the withdrawal and we immediately rebound. we found that people taking more than half a year after discontinuation of hbvdna negative, less than 1 months back, and hbeag cannot be negative. therefore, can't use this medicine to treat hepatitis b virus, unless the liver puncture biopsy confirmed chronic liver. the application can only be considered when the inflammatory pathological changes. 2. acute severe hepatitis or acute liver failure are in critical condition, the ferocious. at this time the patient's main contradiction is not virus replication, some patients even without virus replication index, threatening the patient's life is liver failure, according to "the government ease the emergency treatment of the subject", then the most important is supportive therapy, such as the input of fresh plasma, albumin, artificial liver support therapy. 3. acute exacerbation of chronic hepatitis b, if the transaminase is greater than the upper limit of the normal value of 10 times, there are obvious jaundice, or serum bilirubin than 85.5 mmol / l, temporarily not to take lamivudine and other antiviral drugs, and liver, jaundice and reducing enzyme treatment is given priority to, when remission can apply a small amount. although lamivudine on immune function has strongly influenced not the same interferon but in the acute exacerbation of hepatitis, prevent damage on the immune system. no use is the best policy. 4. chronic hepatitis b in pregnancy or pregnancy after hbv infection, do not use this product, the main reasons of the effect of lamivudine on the fetus are yet to be elucidated. as both at home and abroad, there are application reports and relatively safe, but experts in china has not yet reached a consensus, as a precaution, temporarily application is a wise choice.
chemical property	white solid obtained from methanol- ethyl acetate. [α]d21-132°(c=1.08, methanol). or from the boiling ethanol crystallization, melting point is 160 ~ 162℃. [α]d21-135°(c=0.38, methanol).
application	1. antiviral drugs for hepatitis b. 2. antiviral drugs for the treatment of liver and gallbladder diseases. 3. medicine for liver and gallbladder diseases.
chemical properties	white crystalline powder
usage	a reverse transcriptase inhibitor. antiviral.